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the Decision Resources Group’s ‘Global Market Access Solution’ database were 
reviewed. Results: The healthcare systems in Brazil, Argentina and Mexico are 
decentralised, while that of Colombia is centrally managed. All countries have a 
national health service for all residents, but the proportion of the population that 
relies solely on this varies greatly between countries. In Brazil, 25% of the popula-
tion has private health insurance, while only a small proportion of the popula-
tion relies on private insurance in the other countries. In Mexico and Argentina, 
residents in formal employment are obliged to enrol in one of the social security 
sponsored schemes. In Brazil, Argentina and Colombia, national formularies include 
the mandatory minimum healthcare provision. In Mexico, the national formulary 
is not binding and the different social security schemes decide which treatments 
to cover. The role of health technology assessment (HTA) in the reimbursement 
process varies in different countries. In Brazil, Mexico and Colombia, HTA is criti-
cal in the reimbursement decision process, while in Argentina it has been mostly 
used to assess treatments for catastrophic illnesses; although there is a drive to 
include HTA in the decision process. Opportunities include a growing demand for 
pharmaceuticals, and challenges include decentralised healthcare systems and high 
use of generics. ConClusions: Most countries have a decentralised system where 
reimbursement decision making occurs at the regional level or at the social security 
funds level. HTA is critical in decision making in Brazil, Mexico and Colombia, but 
not yet in Argentina. We have identified current opportunities and challenges for 
the different countries.
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BACkgRound: Evidence bases medicine is the governing principle ruling all aspects 
of a new medical product. Marketing authorization organizations and health tech-
nology agencies focused on the reimbursement aspects of a new product are both 
relying in their decision making process on clinical data of the highest possible 
evidence. While marketing authorization is an increasingly international process 
with standardized rules, the reimbursement process is conducted on a national 
level with country-specific requirements. In some indications, e.g. in chronic dis-
eases, where it is difficult to recruit newly diagnosed patients for clinical trials, 
establishing the efficacy of a product against placebo is a common approach, as 
only patients who did not succeed with the available treatment options are willing 
to participate in these trials. oBjeCtives: To review the national requirements for 
the reimbursement of new medical products with a positive centralized marketing 
authorization based on placebo-controlled clinical trials. We will demonstrate that 
the acceptance of placebo-controlled trials is handled differently between coun-
tries and that different strategies to process these data are necessary. Methods: 
We focused on the national health technology agencies of five representative 
European countries, including the United Kingdom, France, Germany, Sweden and 
the Netherlands. A targeted desktop research on the published methodology and 
the decisions regarding medical products with a marketing authorization based 
on placebo controlled trials for the most recent years was conducted. Results: 
The methodological requirements to get reimbursement for a medical product 
with a marketing authorization based on placebo-controlled trials are different 
in these countries, leading to heterogeneous decisions. ConClusions: Getting a 
positive decision for reimbursement is challenging for products which have mar-
keting authorization based on placebo-controlled trials. The national requirements 
and thresholds for reimbursement are very different and highly dependent on the 
governing principle for evaluation, ranging from quality of life based decisions to 
comparator driven additional benefit decisions.
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oBjeCtives: Resolutions on early benefit assessment can be granted with a time 
restriction, termed “limited”. As a consequence companies are required to resubmit 
their data later. The objective of the present study was to assess reasons for limita-
tion. Methods: The following three criteria are given for limiting a resolution: 
incomplete data on patient relevant endpoints, limited quality of evidence, and 
missing data can be provided at a later stage. Assessment was based on resolutions 
with limitations published until June 2016. For each resolution reasons for limita-
tions were identified and requirements for a resubmission were captured using 
supporting documents (“Tragende Gruende”). Results: 26 out of 130 resolutions 
(20%) were limited with limitations ranging from 1 to 5 years. In 18 resolutions (69%) 
G-BA made reference to missing data on endpoints. In further 18 resolutions the 
G-BA explicitly referred to limited quality of evidence. Expectations for better data 
in the future are mentioned in 13 resolutions (50%). More information on what data 
is required for a reassessment is provided in 8 resolutions (31%). ConClusions: 
Most limitations are made even though they do not meet (all) legal criteria. Missing 
information on the requirements for reassessment increases the risk for subse-
quent failure.
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oBjeCtives: The use of innovative medicines has been associated with increased 
healthcare-related expenditure in the EU5 (Italy, France, Spain, UK and Germany). 
In some countries, this has raised concerns over the clinical and economic assess-
ment of such medicines and has led to the introduction of additional criteria to 
orphan drugs assessments between January 2011 and May 2015 and compari-
son with assessments conducted by HTA agencies in France, Netherlands, the 
UK and Canada, to examine similarities and differences in benefit evaluations, 
reimbursement and drug access. Results: Germany has 23 completed assess-
ments for 21 orphan drugs during the time frame. 9 received non quantifiable 
additional benefit, 11 marginal and 3 significant. Out of 5 drugs where different 
patient subgroups were identified, only 1 (ivacaftor) received different ratings 
across two patient subgroups (marginal and significant). This 21 orphan drug 
sub-set was then compared across the other countries. In France, 19 (90.5%) were 
recommended for reimbursement. Comparing the additional benefit ratings 
assigned in Germany with the French ASMR ratings, we found significantly dif-
ferent value assessments for 15 (78.9%) out of 19 drugs reviewed in both countries. 
In the Netherlands, HTA’s by the National Health Care Institute were available for 
7 (33.3%) drugs: 5 (23.8%) were reimbursed, all with restrictions. SMC reviewed 14 
(66.7%) drugs of which 5 (23.8%) were not recommended (3: non-submission and 2: 
economic considerations). Of the 9 (42.9%) drugs that were recommended, 6 had a 
negotiated patient access scheme (PAS). NICE reviewed 5 (23.8%) drugs, 4 of which 
were for oncology and not recommended for reimbursement. Only one (4.8%) 
drug (pirfenidone) was recommended for restricted use based on a PAS. Canada’s 
CADHT assessed 6 (28.6%) drugs: only 4 (19.0%) were listed with restrictions after 
price reductions. ConClusions: Among the countries examined, Germany had 
the highest number of orphan drugs assessed. Differences in HTA assessment 
criteria lead to noticeably different benefit evaluations, recommendations and, 
ultimately, drug access.
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oBjeCtives: The primary focus of manufacturers’ reimbursement submissions in 
Germany is on demonstrating the added benefit of a product versus the appropri-
ate comparator(s). Some decisions made by Gemeinsamer Bundesausschuss (G-BA) 
result in a time-limited approval, after which there should be a review. This study 
analyses any completed reviews conducted by the G-BA. Methods: G-BA deci-
sions were searched to identify restricted decisions and subsequent reviews. Data 
were extracted, the reasons for the restrictions and the ways these were addressed 
in the reviews, were analysed. Results: 20% (27/135) of all decisions identified 
were time restricted. Restrictions were mainly applied to products with small or 
no added benefit. The most common reason for a restriction was incomplete evi-
dence profiles, and the most common restriction period was three years. Of the 27 
restrictions identified, two reviews have taken place, two restriction periods have 
been extended and five more decisions are expected by the end of 2015. An analysis 
of the completed eribulin review showed that the manufacturer was granted suf-
ficient time to collect additional evidence and that the G-BA adjusted its recom-
mendations in a favourable manner once further evidence was provided. However, 
during the vemurafenib review the level of added benefit did not change from the 
original evaluation. This indicates the manufacturer did not present sufficient data 
to address the original criticism and was therefore unable to raise the level of added 
benefit. Furthermore, it is evident that the G-BA takes regulatory guidance into con-
sideration in decision making. ConClusions: The results indicate that restricted 
decisions provide manufacturers with the opportunity to collect additional data 
and improve the final added benefit recommendation. If manufacturers address 
the G-BA’s criticism of the original submission, more favourable added benefit levels 
can be achieved during the review. Furthermore, it shows that EMA decisions influ-
ence G-BA decision making.
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oBjeCtives: Benefit assessment usually requires RCT data. Orphan drugs are 
granted additional benefit by law, but not drugs with conditional or exceptional 
approval or PUMA. The objective of this study was to assess how their status is 
handled in benefit assessment. Methods: All resolutions until June 2016 were 
analyzed whether they have been approved by EMA under these circumstances. 
Those which do were assessed regarding underlying evidence, extend of additional 
benefit and other aspects of the resolution. Results: 7 out of 104 resolutions (7%) 
met these criteria – 5 with conditional approval, 1 with exceptional circumstances 
and 1 PUMA. 2 out of 7 products had only non-RCT evidence. For 6 products the 
IQWiG found no additional benefit and for 1 product a major additional benefit. The 
G-BA increased three products to minor (or considerable) additional benefit, even 
though one approval was based only on a case series. However, for three products 
the result was still “additional benefit not proven”. 4 out of 7 resolutions had been 
limited. ConClusions: Special regulatory status gives no formal advantage in 
benefit assessment. However G-BA seems to take their status into account and 
using limitations to account for future evidence.
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oBjeCtives: To define the current processes and key decision makers involved 
in gaining market access in Brazil, Argentina, Mexico and Colombia, and identify 
opportunities and challenges to market access in these countries. Methods: 
The websites of the appropriate authorities and agencies in each country and 
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oBjeCtives: Market access entry agreements (MAA) are vital to access the Italian 
Market. MAAs, monitored by an AIFA registry, are divided into outcome based (cost-
sharing) and non-outcome based (risk-sharing and payment-by-results) agreements. 
The objective is to understand the MAA adoption, evolution and utilization vari-
ability among Therapeutic Areas. Methods: The desk-based research was carried 
out by integrating different information sources, from AIFA and Gazzette Ufficiali 
to Regional HTA studies. Data was gathered for all the 82 products/indications 
belonging to an open registry signed up to a MAA since January 2006 up until April 
2015. Results: 59% products/indications have an outcome based MAA, 33% a 
non-outcome based and 1% both. A third of outcome based and a quarter of non-
outcome based MAAs have an additional volume agreement or spending cap. A 
maximum peak of 30 products/indications with MAA is recorded in 2014, compared 
to an annual average of 8. In 2006-2007 cost-sharing MAAs were predominantly 
adopted; in 2008-2011, outcome based MAAs were negotiated in approximately half 
of the cases (57%), becoming since 2012, the preferred conditional reimbursement 
scheme (78%). Focusing on Antineoplastic products, Leukemia drugs have only non-
outcome based agreements, Lymphoma, Melanoma, Breast, Colorectal and Ovary 
Cancer drugs have a prevalence of outcome based, whereas Renal Cell and Lung 
Cancer drugs have both. ConClusions: Throughout the years there has been an 
increase in the adoption of a MAAs as they are considered a valuable strategy to 
manage payer budget impact and drug clinical benefit uncertainties. Since their 
introduction, the choice of MAA schemes utilized has witnessed an evolution, with 
an increasing preference for outcome based MAAs, though often applied together 
with additional financial saving schemes. Due to the model adoption variability of 
MAAs within the Therapeutic Areas, the study of their structure plays a key role in 
accessing the Italian Market.
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oBjeCtives: We assessed NHS progress between 2004/5 and 2011/12 in reducing 
inequality in healthcare access and outcomes, with the aim of developing the first 
systematic approach to monitoring socioeconomic inequalities in NHS access and 
outcomes. Methods: Indicators of healthcare access and outcomes at different 
stages of the patient pathway were constructed for all English small areas (2001 
LSOAs) from 2004/5 to 2011/12 using GMS, QOF, HES and ONS mortality and popula-
tion data – (1) GP supply: full time equivalent (FTE) GPs per 100,000 population, need-
weighted adjustment, (2) primary care quality: quality and outcomes framework 
performance, weighted by public health impact, (3) hospital waiting time: days from 
referral-to-treatment, allowing for patient-level casemix, (4) post-hospital mortality: 
12-month mortality after discharge, allowing for patient-level casemix, (5) amenable 
mortality: deaths from causes amenable to health care per 100,000 population, indi-
rectly age-sex-standardised. Slope and relative indices of inequality were calculated 
through small-area-level regression using all 32,482 Index of Multiple Deprivation 
2010 ranks, with regression-based tests of change over time. Results: Nationally, 
all unadjusted relative indices of inequality fell from 2004/5 to 2011/12 (with 95% 
CIs in brackets, where negative indices represent “pro-poor” inequality): (1) for GP 
supply from -2.2% [-2.9% to -1.6%] to -9.5% [-10.2% to -8.8%], (2) for primary care 
quality from 4.1% [3.6% to 4.6%] to 1.1% [0.6% to 1.6%], (3) for hospital waiting time 
from 3.2% [2% to 4.4%] to 2.7% [1.5% to 3.8%], (4) for post-hospital mortality from 
0.6% [2.3% to -1.2%] to -4.5% [-2.6% to -6.4%], and (5) for amenable mortality from 34% 
[36.5% to 31.4%] to 11.9% [14.6% to 9.2%]. ConClusions: Socioeconomic inequal-
ity in healthcare access and outcomes in the English NHS reduced between 2004/5 
and 2011/12 in both relative and absolute terms on all our indicators (unadjusted), 
though all indicators except GP supply and post-hospital mortality continue to 
exhibit “pro-rich” inequality.
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oBjeCtives: Risk minimization interventions (RMIs) implemented by drug manu-
facturers aim at optimizing the benefit-risk of medicines when important safety 
concerns related to product have been identified. In some situations, strict RMIs, 
such as controlled distribution programs or mandatory certification, may be 
required. Although aiming to improve patient’s safety, RMIs could be costly, time-
consuming, challenging and therefore, generate an undue burden on stakeholders. 
In some instances, regulatory agencies request that burden of RMIs be evaluated 
but no methodological guidance is available. The objective of the present study is 
to identify current methodologies used to evaluate the utility and burden associ-
ated with RMIs and to identify methodological gaps. Methods: A non-systematic 
literature review was conducted using Medline and Embase in order to identify 
relevant publications that include an assessment of the utility and/or burden of 
RMI. Pragmatic searches using Google and Google Scholar search engines com-
pleted this analysis. Regulatory agencies websites were also consulted to identify 
potential existing guidelines related to the evaluation of the burden associated 
with RMIs. Results: A total of 362 relevant publications were identified in the 
literature. Among the methods used, surveys and focus groups appeared to be the 
most frequent as they allow to gather participants’ opinions providing a better 
understanding of the burden and potentially identifying optimization opportu-
nities. Mixed-method evaluations were also currently employed as they include 
guide their evaluation and use. While a need to stimulate pharmaceutical inno-
vation is widely recognized, cost containment is significant in decision-making. 
The objective of this research is to identify how members of the EU5 assess the 
innovative value of pharmaceuticals; understand the policies surrounding their 
market access and highlight potential drivers. Methods: We assessed publicly 
available country guidelines and regulations to understand the evaluation and 
reimbursement process for innovative medicines. Findings were considered in 
light of definitions of innovation, market access conditions, reimbursement agree-
ments and sources of funding. Results: Across the EU5, definitions for innova-
tive medicines vary. In Italy, the approach involves an algorithm which forms the 
basis of the assessment and reimbursement process for innovative medicines at 
national level. In Spain, although innovation is considered alongside clinical and 
economic parameters in the evaluation of drugs, there are no special considera-
tions for reimbursement. France and Germany are both found to value innovation 
as a core criterion in the standard appraisal process with opportunities to facilitate 
market access in France and with prospects for price negotiations in Germany. In 
the UK, innovation is included as a modifying factor; however, the recently intro-
duced Early Access to Medicines Scheme, allows the UK to present a landscape 
facilitating the development of innovative medicines. ConClusions: There are 
similarities and differences in the approaches used by the EU5 country members 
in their assessment and reimbursement of innovative medicines. While in some 
countries, innovative medicines benefit from lowered hurdles for market access; 
in other countries, innovation proves less impactful.
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oBjeCtives: Patient Access Schemes (PAS) are agreed between pharmaceutical 
companies and the Department of Health (DoH, with input from National Institute 
of Health and Care Excellence [NICE]) that enable companies to offer discounts 
or rebates that reduce the cost of a drug. PAS proposals are made in the context 
of a NICE technology appraisal, with the aim of improving cost-effectiveness to 
enable a positive NICE recommendation. This research aims to systematically ana-
lyse all PASs for NICE- approved technologies with respect to the type of scheme 
agreed, indication, company and how these have varied over time. Methods: 
Publically available technologies with approved PASs were identified from the NICE 
website and the date, treatment, indication, company, and type of scheme were 
extracted. Results: 49 PAS were identified involving 25 different companies. 51% 
(25/49) were for oncology medicines, 16% (8/49) rheumatology, 12% (6/49) ophthal-
mology, 6% (3/49) MS, and 14% (7/49) other. 76% (37/49) of PASs were simple dis-
counts, 14% (7/49) for free stock, 6% (3/49) dose caps, 2% (1/49) rebates, and 2% (1/49) 
response schemes. An average of 5.4 new PASs are agreed every year, but these have 
risen from 3 between 2007-2008 to 23 in 2013-2014. There is also a notable time trend 
in the type of PAS, with 97% (32/33) of PASs agreed since November 2011 being simple 
discounts versus only 31% (5/16) of those agreed beforehand. ConClusions: PASs 
have been utilised by many pharmaceutical companies to help gain NICE approval 
primarily in oncology. Their utilisation has notably increased in recent years along-
side a very strong trend to almost exclusively be simple discount schemes, perhaps 
reflecting DoH aversion to managing more complex schemes. Nevertheless, the 
recent dose capping PAS agreed with GSK for Tafinlar in October 2014, illustrate that 
other types of schemes will still be considered acceptable by the DoH.
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oBjeCtives: IVIgs are used off-label in a number of patients with rare diseases 
which is thought to be mostly responsible for their increasing use. We propose 
here to describe the market access framework set in the EU5 for IVIgs’ off-label use 
and determine if the level of evidence supporting off-label use influences its fund-
ing. Methods: A literature review has been carried out in May 2015 using Pubmed 
and Datamonitor databases as well as websites of European Health authorities 
using the following terms: [off-label use OR unlicensed] AND [intravenous immuno-
globulin] AND [funding OR reimbursement]. Results: Despite its common practice, 
there is little regulation for off-label use and is generally funded when no approved 
therapeutic alternative exists. Schemes allowing pragmatic solutions for the funding 
of off-label use have been recently implemented in France through the granting of 
Temporary Recommendations for Use (RTUs), in Italy through pre-authorisation 
by AIFA (lista farmaci off label), in Germany with the implementation of BfARM 
off-label expert group. Funding through these schemes is granted if evidence of 
treatment success are shown and that there is no therapeutic alternatives. However, 
these schemes do not currently cover all drugs, including IVIgs. There is evidence 
of funding for IVIgs’ off-label use in Spain but no specific schemes are set up. In the 
UK, the Department of Health implemented a Demand Management Programme 
for IVIgs. Their indications are colour-coded according to their level of priority and 
funding is linked to the colour granted. We found that IVIg’s off-label use is funded if 
judged of a high priority. ConClusions: IVIgs’ off-label use funding is not equally 
regarded in the EU5. Harmonisation of off-label use funding, dependant on the level 
of evidence available, may be considered in the future to ensure equal access to IVIg 
therapy amongst European patients.
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